TAVNEOS
Peakavacopan
NDAORALCAPSULE
Approved
Oct 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
12
Data completeness
6/8 — Strong
TAVNEOS (avacopan) is complement 5a receptor antagonists [moa]. Approved for anca-associated vasculitis, granulomatosis with polyangiitis. First approved in 2021.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAVNEOS (avacopan) is an oral complement 5a receptor antagonist approved by the FDA on October 7, 2021, for the treatment of ANCA-associated vasculitis (AAV). It works by blocking the C5a complement pathway, which plays a key role in the inflammatory cascade driving vasculitis. TAVNEOS represents a novel mechanism-of-action approach that addresses unmet needs in a rare disease with limited treatment options historically dominated by corticosteroids and immunosuppressants.
$0.0BPart D
13.6 years to LOEMechanism of Action
Complement 5a Receptor Antagonists
Pharmacologic Class:
Complement 5a Receptor Antagonist
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.